Liang Schweizer is the Co-founder, Chairman and Chief Executive Officer of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise.

Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates.

Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

Francisco Adrian is the Chief Scientific Officer at HiFiBiO Therapeutics. He is an accomplished scientist with more than 20 years of experience in drug discovery and pharmaceutical research and development.

Previously, Dr. Adrian worked as a Director at the Sanofi Oncology Division, where he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Before joining Sanofi, he was a Group Leader at the Genomics Institute of the Novartis Research Foundation focused on the discovery of novel kinase inhibitors for Oncology indications.

Dr. Adrian graduated in Organic Chemistry and Biochemistry and received his PhD in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris.

Dr. Luigi Manenti is the Chief Medical Officer at HiFiBiO Therapeutics. He is a seasoned physician scientist with extensive experience designing and executing innovative clinical trials with a strong expertise in translational clinical oncology.

Previously, Dr. Manenti served as the Team Leader for Solid Tumors in Global Pipeline Strategy at Novartis Oncology Business Unit where he oversaw the early commercial and pipeline strategy for various internal and external assets. Prior to this role, he worked at the Novartis Institutes for BioMedical Research as Global Clinical Program Leader, leading multiple programs including capmatinib (Tabrecta) and MBG453 (sabatolimab). His earlier roles include multiple positions at Roche in Switzerland and China including Translational Medicine Site head.

Dr. Manenti holds an MD in Medicine and Surgery from the University of Pavia.

John Pallante is the Vice President, Global Head of Clinical Operations at HiFiBiO Therapeutics. He has over 15 years of clinical operations experience preparing and executing global clinical trials alongside partners and collaborators.

Prior to HiFiBiO, Mr. Pallante served as the Global Head of Clinical Quality Management and Training at Novartis Institutes for BioMedical Research. Before then, he held various leadership roles at Novartis in the areas of Governance and Operational Excellence, Clinical Operations, and Clinical Trial Intelligence.

John Pallante earned his MS from Temple University and BS from Rutgers, The State University of New Jersey-Camden.

Dr. Christos Hatzis is the Vice President, Global Head of Clinical Pharmacogenomics at HiFiBiO Therapeutics. He is an engineer by training with extensive translational and immune-oncology experience and an entrepreneurial mindset.

Prior to HiFiBiO, Dr. Hatzis was a Director, Tumor Strategy Lead, Translational Medicine at Bristol-Myers Squibb where he provided scientific and strategic leadership for the solid tumor programs. Before BMS, he served as an Associate Professor for the Department of Internal Medicine (Medical Oncology) at Yale University School of Medicine, where he still holds an Adjunct faculty position. Earlier in his career, he co-launched two start-up companies, Silico Insights and Nuvera Biosciences, an informatics and data mining company and ventured-funded spin off the MDACC respectively.

Edward Rocnik is the Vice President, Global Head of CMC at HiFiBiO Therapeutics. He is a seasoned scientist with over 12 years of experience in CMC and research related roles.

Previously, Dr. Rocnik has held various CMC and research roles at Takeda, Millennium, and Organogenesis. Most recently, he served as Director, Head of Late-Stage Analytical Development, Cell Therapies at Takeda.

Dr. Rocnik earned his PhD and BS from Western University.

Jinping Gan is the Executive Director, Global Head of Antibody Discovery and Optimization (ADO) at HiFiBIO. He is a biological chemist with 20 years of biopharma industry experience.

Jinping has strong expertise in drug metabolism, pharmacokinetics and pharmacodynamics, and chemical toxicology. Jinping previously worked at Bristol-Myers Squibb, focusing on preclinical optimization and characterization of diverse pipeline molecules from early discovery to NDA filings. Jinping held a PhD in Biological Chemistry from MIT , and a BS in Analytical Chemistry from University of Science & Technology of China.

Andreas is leading the company’s global efforts to support pipeline progression by applying the latest advances in data science, machine learning and artificial intelligence on translationally relevant data sets. Dr. Raue brings more than 10 years of experience in computational science, as well as several years of industry leadership experience in immune-oncology antibody development at Merrimack Pharmaceuticals. Andreas received his PhD in theoretical physics from the University of Freiburg where he applied computational modeling and analysis to biological and medical problems. His research has been published in various scientific journals and presented at international conference. Dr. Raue is inspired by the potential of leveraging innovative single-cell technologies and machine learning for the advancement of cancer research.

Rachel Yao is the Financial Controller at HiFiBiO Therapeutics and carries extensive knowledge and working experience in finance and audit for the life science industry.

Previously, Rachel worked for Ernst & Young (EY) for more than 11 years, providing multinational clients assurance and services related to Hong Kong capital markets. She is familiar with IFRS/HKFRS reporting framework, IFRS/HKFRS updates and Hong Kong listing rules. Moreover, she served as an EY industry expert on pharmaceutical manufacturing and distribution.

Rachel holds a CPA (Certified Public Accountant) certification from China and Australia and a BS degree in Accounting from Shanghai University of Finance & Economics.

Vincent Tse is the Director of Staff and Strategy at HiFiBiO Therapeutics. His professional experience includes R&D Product Development, Business Development, and Strategy Consulting for both small biotech and large pharma.

Vincent previously worked for Genentech, conducting competitive intelligence for the company’s asthma portfolio. Prior to Genentech, he performed Product and Business Development for Armata Pharmaceuticals, an innovative biotech focused on therapeutics against antibiotic-resistant infections. Most recently, he was a strategy and portfolio analysis consultant for IQVIA with diverse engagements in digital therapeutics, rare disease, and oncology.

Vincent earned an MBA from Duke University Fuqua School of Business, an MS in FDA Regulatory Affairs from Northeastern University, and a BS degree in Physiological Science from UCLA.

He Zhou is leading the global efforts in pharmacology to support the company’s internal pipeline. She brings more than 18 years of experience in Immuno-Oncology. Before joining HiFiBiO Therapeutics, Dr. Zhou participated in the clinical development of multiple Immuno-Oncology drugs at different stages as Senior Director of Clinical Biomarkers at BeiGene Ltd. in Beijing, China. Prior to working at BeiGene, she also served as Vice President of Biology, Pharmacology and Toxicology at Tayu Huaxia Biotech Medical Group Co. Ltd., Executive Director and Head of Pharmacology at Shanghai ChemPartner Co. Ltd., and Senior Scientist at Momenta Pharmaceuticals Inc.

Dr. Zhou received a bachelor’s degree in medicine and a master’s degree in Immunology from Beijing University Health Science Center (formerly Beijing Medical University), as well as a PhD degree in Immunology from the University of Mississippi Medical Center. She received her postdoc training in Dr. Ralph Reisfeld’s Laboratory in Immuno-Oncology at The Scripps Research Institute.

Sami Ellouze is the Director, France General Manager at HiFiBiO Therapeutics. He is an engineer and scientist with over 7 years of experience working with and optimizing single cell technologies for both internal drug discovery programs and external partnerships.

Previously, Sami was involved in NGS data analysis and biomarker identification for a novel metabolomics approach. Sami holds an engineering degree in Conception and Innovation of Bioproducts from the University of Technology of Compiègnem.

Dr. Roshan Kumar is the Senior Director, US External Innovation at HiFiBiO Therapeutics. He is a scientist with over 15 years of experience in the study of complex biological systems.

Roshan leads US External Innovation activities to identify high impact partnerships and collaborations for the company’s internal pipeline and DIS™ platform. Dr. Kumar’s previous research was focused on the study of transcriptional regulatory networks in mammalian systems, and on understanding how cellular heterogeneity influences fate decisions in individual pluripotent stem cells.

Dr. Kumar received his PhD in Biochemistry from the Scripps Research Institute and Bachelor’s degrees in Chemistry and Biology from the California Institute of Technology. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.